Replies to post #6344 on Nutra Pharma Corp (NPHC)

[nole92]

I think you both are incorrect, of course.

Where was Cobroxin 3 months ago? You guys want a quick buck, but the truth is we are ahead of the schedule laid out by NPHC.

You say 'Nyloxin, of course, has the potential to turn things around.' Turn what around? I guess you mean the unrealistic expectations of some message board posters?

'Competition for shelf space is fierce.' Since you post this like you are in the know, you can agree of what a great job XCHO/NPHC has done to get on the shelf of half of the drug stores in the US in the past few months.

[gator97]

I think its a little early to say Cobroxin "failed". If anything, it has made an impressive launch. I don't profess to know the history of success for OTC pain relievers, but I for one think Cobroxin had made serious inroads since becomming available late last year. We will see what the reorder rates are soon. That will give us a better idea of where this product is heading. After that, wait to see what the effect of the advertising has on Q3 sales. At that point we those that care can bump their chests or hide in a hole, depending on their current bullish or bearish sentiments.

[Ida Ho]

NAGA - BINGO you hitthe nail onthe head. Nyloxin is NOT a in reality a complimentary product. IT IS A SAVIOR for a what is a fizzling Cobroxin. Read the marketing materials on the companies own web sites and ANYONE please tell me WHY you would even consider a purchase of Cobroxin versus Nyloxin. If product A will take away your pain but product B will do it twice as good, ALL willw ant product B.

Coborxin and XCHO had its chance to step up to the plate and while I will admit that they have not yet struck out . . . the count is 0 - 2 and they cant hit a good slider that is surely coming their way.